In recent years, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy has been shown to display superior efficacy compared to standard chemotherapy (Ettinger et al., 2017), and has profoundly impacted the therapeutic landscape of NSCLC (Yuan et al., 2019; Lynch et al., 2004). This evidence concerns the gene EGFR and non-small cell lung carcinoma.